中药防护治疗方案联合化疗治疗非小细胞肺癌临床研究

发布时间：2018-06-21 15:22

本文选题：非小细胞肺癌 + 中药防护治疗方案　；参考：《中华中医药杂志》2017年08期

【摘要】：目的:观察中药防护治疗方案联合化疗治疗非小细胞肺癌的临床疗效和安全性。方法:将80例非小细胞肺癌患者随机分成治疗组和对照组。两组均接受NCCN指南标准连续化疗2个周期(21d为1个周期),治疗组在对照组基础上联合使用中药防护治疗方案(口服中药汤剂+口服中成药+静脉滴注中药注射剂),2个周期后观察两组的瘤体客观疗效、生活质量、不良反应和机体免疫功能。结果:治疗组与对照组瘤体客观疗效有效率分别为38.9%和33.3%,治疗组有效率高于对照组,但是差异无统计学意义;治疗组在提高生活质量、减轻化疗不良反应、改善机体免疫力方面均优于对照组(P0.01,P0.05)。结论:非小细胞肺癌患者采用中药防护治疗方案联合化疗的临床疗效优于单纯化疗,值得临床大力推广。
[Abstract]:Objective: to observe the clinical efficacy and safety of traditional Chinese medicine (TCM) combined with chemotherapy in the treatment of non-small cell lung cancer (NSCLC). Methods: 80 patients with non-small cell lung cancer were randomly divided into treatment group and control group. Both groups received NCCN standard continuous chemotherapy for 2 cycles and 21 days as one cycle. The treatment group was treated with traditional Chinese medicine prophylaxis on the basis of the control group (oral Chinese traditional medicine decoction, oral Chinese patent medicine intravenous drip of traditional Chinese medicine injection), and the treatment group was treated with traditional Chinese medicine prophylaxis on the basis of the control group. After 2 cycles, the objective curative effect of the two groups was observed. Quality of life, adverse reactions and immune function. Results: the effective rates of the treatment group and the control group were 38.9% and 33.33.The effective rate of the treatment group was higher than that of the control group, but the difference was not statistically significant. The improvement of body immunity was better than that of the control group (P 0.01 and P 0.05). Conclusion: the clinical curative effect of traditional Chinese medicine combined with chemotherapy in patients with non-small cell lung cancer is better than that of chemotherapy alone, and it is worth popularizing in clinic.
【作者单位】：湖南中医药大学;湖南中医药大学附属中西医结合医院肿瘤科;
【基金】：国家中医药管理局中医药行业科研专项(No.201307006)~~
【分类号】：R734.2

【参考文献】